EnteroBiotix Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EnteroBiotix Limited - overview
Established
2017
Location
Bellshill, Scotland, UK
Primary Industry
Biotechnology
About
Founded in 2017 by CEO Dr James McIlroy and based in UK, EnteroBiotix Limited is a biopharmaceutical company that researches and develops treatments using the human microbiome. In April 2026, EnteroBiotix Limited raised GBP 19 million in venture funding co-led by Thairm Bio and Scottish National Investment Bank. EnteroBiotix Limited specializes in microbiome medicine, utilizing the gut microbiome to prevent and treat diseases. Their Faecal Microbiota Transplantation (FMT) is a treatment that involves the transfer of microbial communities from one person into another with the intention of treating or preventing a disease.
Additionally, the company’s platform offers full-spectrum microbiome products, replicating the beneficial components of a healthy gut in a dried, colorless, and odorless powder. This method surpasses traditional, less effective approaches like liquid suspensions and invasive procedures. Notable products include EBX-102, which is in Phase 2 clinical trials for conditions such as Irritable Bowel Syndrome (IBS) and liver diseases. The company plans to use the April 2026 funding to advance the development of its lead candidate, EBX-102-02, into Phase 2b for Irritable Bowel Syndrome with Constipation.
Current Investors
Equity Gap, Bank Workers Charity, SyndicateRoom
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.enterobiotix.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
EnteroBiotix Limited - financials
| Fiscal Year Ended | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - |
| NET Income (USD) | (538,651) | (970,522) | (2,005,050) | (7,741,190) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - |
EnteroBiotix Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | EnteroBiotix Limited | - | ||||||||
| Series B | Completed | EnteroBiotix Limited | - | ||||||||
| Series A | Completed | EnteroBiotix Limited | - | ||||||||
| Seed | Completed | EnteroBiotix Limited | - | ||||||||
| Unspecified Round | Completed | EnteroBiotix Limited | - |
Displaying 1 - 5 of 6
EnteroBiotix Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.